Novo Nordisk received approval for its Wegovy weight-loss pill in December, and its been on the market for a few months
The following primary antibodies were used: anti-MC5-R (Alomone Labs, Jerusalem, Israel, # AMR-025), anti--MSH (Bioss, MA, USA, # BS-1848R), anti-phospho-JNK (Cell Signaling Tech, # 4668), anti-JNK (R&D Systems, # AF-1387), anti-phospho-ERK1/2 (Cell Signaling Tech, # 9107), anti-ERK1/2 (Cell Signaling Tech, # 9106), anti-phospho-p38 (Cell Signaling Tech, # 9215), anti-p38 (Cell Signaling Tech, # 9212), anti-phospho-AMPK (Cell Signaling Tech, # 2535), anti-AMPK (Cell Signaling Tech, # 2532), anti-phospho-Akt (R&D Systems, # AF887), anti-Akt (R&D Systems, # MAB2055), anti-phospho-CREB (ThermoFisher, # MA5-11192), anti-CREB (Cell Signaling Tech, #9197) and anti-NT-proBNP (Abcam, # ab13115) antibody
Gutierrez-Aguilar R, Woods SC
The pathological characteristics of the vehicle group were consistent with the clinical definitions of IF/TA and i-IFTA based on the Banff classification
